116 related articles for article (PubMed ID: 31705546)
1. Cutaneous blastic plasmacytoid dendritic cell neoplasm arising in the context of TET2 and ZRSR2 mutated clonal cytopenias of unknown significance, secondary to somatic copy number losses involving CDK2NA/2NB and MTAP.
Li M; Shah M; Binder M; Lasho T; Carr R; Mangaonkar A; Gangat N; Coltro G; Tefferi A; Dao L; Peters M; Chiu A; Patnaik MM
Am J Hematol; 2020 Feb; 95(2):E31-E34. PubMed ID: 31705546
[No Abstract] [Full Text] [Related]
2. Blastic plasmacytoid dendritic cell neoplasm arising from clonal hematopoiesis.
Suma S; Sakata-Yanagimoto M; Nguyen TB; Hattori K; Sato T; Noguchi M; Nannya Y; Ogawa S; Watanabe R; Fujimoto M; Nakamura N; Kusakabe M; Nishikii H; Kato T; Chiba S
Int J Hematol; 2018 Oct; 108(4):447-451. PubMed ID: 29705980
[TBL] [Abstract][Full Text] [Related]
3. TET2 and TP53 mutations are frequently observed in blastic plasmacytoid dendritic cell neoplasm.
Jardin F; Ruminy P; Parmentier F; Troussard X; Vaida I; Stamatoullas A; Leprêtre S; Penther D; Duval AB; Picquenot JM; Courville P; Capiod JC; Tilly H; Bastard C; Marolleau JP
Br J Haematol; 2011 May; 153(3):413-6. PubMed ID: 21275969
[No Abstract] [Full Text] [Related]
4. Venetoclax monotherapy for cutaneous blastic plasmacytoid dendritic cell neoplasm.
Schwede M; Tan IT; Atibalentja DF; Dickman MM; Rieger KE; Mannis GN
Ann Hematol; 2020 Dec; 99(12):2973-2975. PubMed ID: 32968828
[No Abstract] [Full Text] [Related]
5. Mutated ZRSR2 and CUL3 accelerate clonal evolution and confer venetoclax resistance via RAS signaling pathway in blastic plasmacytoid dendritic cell neoplasm.
Fukuchi K; Koyama D; Takada M; Mori H; Hayashi K; Asano N; Sato Y; Fukatsu M; Takano M; Takahashi H; Shirado-Harada K; Kimura S; Yamamoto T; Ikezoe T
Int J Hematol; 2023 Oct; 118(4):489-493. PubMed ID: 37029861
[TBL] [Abstract][Full Text] [Related]
6. Chronic myelomonocytic leukemia and blastic plasmacytoid dendritic cell neoplasm. A case report and systematic review.
Espasa A; Sorigue M; Tapia G; Cabezon M; Vergara S; Raya M; Navarro JT; Junca J; Zamora L; Xicoy B
Cytometry B Clin Cytom; 2021 May; 100(3):292-295. PubMed ID: 32830878
[No Abstract] [Full Text] [Related]
7. Blastic plasmacytoid dendritic cell neoplasm with unusual morphology, MYC rearrangement and TET2 and DNMT3A mutations.
Kurt H; Khoury JD; Medeiros LJ; Huh YO
Br J Haematol; 2018 May; 181(3):305. PubMed ID: 29411884
[No Abstract] [Full Text] [Related]
8. Sex-Biased
Togami K; Chung SS; Madan V; Booth CAG; Kenyon CM; Cabal-Hierro L; Taylor J; Kim SS; Griffin GK; Ghandi M; Li J; Li YY; Angelot-Delettre F; Biichle S; Seiler M; Buonamici S; Lovitch SB; Louissaint A; Morgan EA; Jardin F; Piccaluga PP; Weinstock DM; Hammerman PS; Yang H; Konopleva M; Pemmaraju N; Garnache-Ottou F; Abdel-Wahab O; Koeffler HP; Lane AA
Cancer Discov; 2022 Feb; 12(2):522-541. PubMed ID: 34615655
[TBL] [Abstract][Full Text] [Related]
9. Cytogenetics of Blastic Plasmacytoid Dendritic Cell Neoplasm: Chromosomal Rearrangements and DNA Copy-Number Alterations.
Sakamoto K; Takeuchi K
Hematol Oncol Clin North Am; 2020 Jun; 34(3):523-538. PubMed ID: 32336417
[TBL] [Abstract][Full Text] [Related]
10. Alterations of the cell-cycle inhibitors p27(KIP1) and p16(INK4a) are frequent in blastic plasmacytoid dendritic cell neoplasms.
Wiesner T; Obenauf AC; Cota C; Fried I; Speicher MR; Cerroni L
J Invest Dermatol; 2010 Apr; 130(4):1152-7. PubMed ID: 19924135
[TBL] [Abstract][Full Text] [Related]
11. In vivo and in vitro sensitivity of blastic plasmacytoid dendritic cell neoplasm to SL-401, an interleukin-3 receptor targeted biologic agent.
Angelot-Delettre F; Roggy A; Frankel AE; Lamarthee B; Seilles E; Biichle S; Royer B; Deconinck E; Rowinsky EK; Brooks C; Bardet V; Benet B; Bennani H; Benseddik Z; Debliquis A; Lusina D; Roussel M; Solly F; Ticchioni M; Saas P; Garnache-Ottou F
Haematologica; 2015 Feb; 100(2):223-30. PubMed ID: 25381130
[TBL] [Abstract][Full Text] [Related]
12. Blastic plasmacytoid dendritic cell neoplasm with genetic mutations in multiple epigenetic modifiers: a case report.
Dang X; Zhou D; Meng L; Bi L
J Int Med Res; 2021 Feb; 49(2):300060520982667. PubMed ID: 33530792
[TBL] [Abstract][Full Text] [Related]
13. Blastic plasmacytoid dendritic cell neoplasm with immunoblastoid morphology and MYC rearrangement and overexpression.
Chang KC; Yu-Yun Lee J; Sakamoto K; Baba S; Takeuchi K
Pathology; 2019 Jan; 51(1):100-102. PubMed ID: 30482401
[No Abstract] [Full Text] [Related]
14. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): a rare entity.
Lim MS; Lemmert K; Enjeti A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26791132
[TBL] [Abstract][Full Text] [Related]
15. Molecular Features of Blastic Plasmacytoid Dendritic Cell Neoplasm: DNA Mutations and Epigenetics.
Sapienza MR; Pileri S
Hematol Oncol Clin North Am; 2020 Jun; 34(3):511-521. PubMed ID: 32336416
[TBL] [Abstract][Full Text] [Related]
16. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
Schaub FX; Looser R; Li S; Hao-Shen H; Lehmann T; Tichelli A; Skoda RC
Blood; 2010 Mar; 115(10):2003-7. PubMed ID: 20061559
[TBL] [Abstract][Full Text] [Related]
17. TET2 gene sequencing may be helpful for myeloproliferative neoplasm diagnosis.
Verger E; Andreoli A; Chomienne C; Kiladjian JJ; Cassinat B
Br J Haematol; 2014 May; 165(3):416-9. PubMed ID: 24433485
[No Abstract] [Full Text] [Related]
18. TET2 truncating mutations predict a worse outcome in blastic plasmacytoid dendritic cell neoplasm.
Beird H; Yin CC; Khoury JD; Pierce S; Abbas HA; Zhao L; Skwarska A; Qazilbash M; Konopleva M; Futreal PA; Pemmaraju N
Blood Adv; 2023 May; 7(10):2000-2003. PubMed ID: 36689729
[No Abstract] [Full Text] [Related]
19. Divergent clonal evolution of blastic plasmacytoid dendritic cell neoplasm and chronic myelomonocytic leukemia from a shared TET2-mutated origin.
Batta K; Bossenbroek HM; Pemmaraju N; Wilks DP; Chasty R; Dennis M; Milne P; Collin M; Beird HC; Taylor J; Patnaik MM; Cargo CA; Somervaille TCP; Wiseman DH
Leukemia; 2021 Nov; 35(11):3299-3303. PubMed ID: 33833384
[No Abstract] [Full Text] [Related]
20. p15 Expression Differentiates Nevus from Melanoma.
Taylor LA; O'Day C; Dentchev T; Hood K; Chu EY; Ridky TW; Seykora JT
Am J Pathol; 2016 Dec; 186(12):3094-3099. PubMed ID: 27855847
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
